Revolution Medicines RVMD
Revolution Medicines, Inc. · Nasdaq · Biological Products, (No Diagnostic Substances) · also RVMDW
$190.27+0.82%close on Oct. 29, 2026 · volume 1.3M · Yahoo Finance
Price, last 48 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 26, 2026 | Anthony Mancini See Remarks | Sold 10b5-1 plan | 2,310 | $186.99 | $431,947 |
| Sept. 29, 2026 | Alan B. Sandler Chief Development Officer | Sold 10b5-1 plan | 6,309 | $202.14 $200.82-$204.72 | $1.28 million |
| Sept. 25, 2026 | Jeff Cislini SVP & General Counsel | Sold 10b5-1 plan | 765 | $207.32 | $158,600 |
| Sept. 25, 2026 | Anthony Mancini See Remarks | Sold 10b5-1 plan | 3,121 | $200.54 | $625,885 |
| Sept. 24, 2026 | Anthony Mancini See Remarks | Sold 10b5-1 plan | 587 | $200.00 | $117,400 |
| Sept. 22, 2026 | Elizabeth M. Anderson director | Sold 10b5-1 plan | 10,143 | $193.04 $191.85-$195.15 | $1.96 million |
| Sept. 18, 2026 | Anthony Mancini See Remarks | Sold 10b5-1 plan | 1,764 | $196.94 | $347,402 |
| Sept. 16, 2026 | Alan B. Sandler Chief Development Officer | Sold 10b5-1 plan | 341 | $199.24 $194.96-$199.30 | $67,941 |
| Sept. 16, 2026 | Anthony Mancini See Remarks | Sold 10b5-1 plan | 1,774 | $199.24 $195.05-$199.30 | $353,449 |
| Sept. 16, 2026 | Stephen Michael Kelsey See Remarks | Sold 10b5-1 plan | 5,569 | $199.24 $195.01-$199.30 | $1.11 million |
| Sept. 16, 2026 | Margaret A. Horn Chief Operating Officer | Sold 10b5-1 plan | 4,967 | $199.24 $195.01-$199.30 | $989,613 |
| Sept. 16, 2026 | Mark A. Goldsmith See Remarks, director | Sold 10b5-1 plan | 13,988 | $199.24 $195.01-$199.30 | $2.79 million |
Latest 12 of 21. Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 28 →Creation of a direct financial obligation · Other events